Finance

Beta
Ask
Lists
ISRG:NASDAQ
Intuitive Surgical Inc
$403.74
+0.14%
(+0.56) 1D
Jun 24, 10:40:54 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ISRG...
Open
$406.00
High
$412.54
Low
$403.78
Mkt. cap
143.12B
Avg. vol.
2.52M
Volume
447.73K
P/E ratio
48.98
52-wk high
$603.88
52-wk low
$396.68
EPS
$8.24
Beta
1.46
Shares outstanding
354.16M
No. of employees
17K
Open
$406.00
High
$412.54
Low
$403.78
Mkt. cap
143.12B
Avg. vol.
2.52M
Volume
447.73K
P/E ratio
48.98
52-wk high
$603.88
52-wk low
$396.68
EPS
$8.24
Beta
1.46
Shares outstanding
354.16M
No. of employees
17K
News stories
From sources across the web
Profile
Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S., 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world. Intuitive Surgical first appeared on the Fortune 500 in 2024 at number 497; in 2025 the company rose to number 459 overall and ranked 43rd within the healthcare sector. Wikipedia
About Intuitive Surgical Inc
CEODavid J. Rosa
Employees17K
Founded1995
HeadquartersSunnyvale, California, United States
SectorMedical device
Websiteintuitive.com
Analyst Ratings
Based on 19 analysts giving stock ratings to ISRG in the past 3 months
Buy
Buy
14
Hold
4
Sell
1
12 month forecast
Based on 19 Wall Street analysts offering 12 month price targets for ISRG in the last 3 months.
Highest
Current $403.74
$670.00 (+65.95%)
Average
$561.33 (+39.03%)
Lowest
$366.00 (-9.35%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Ryan Zimmerman
BTIG
Buy
Maintained
$574.00
+42.2%
06/22/2026
David Roman
Goldman Sachs
Buy
Reiterated
$558.00
+38.2%
06/15/2026
Travis Steed
Bank of America Securities
Buy
Reiterated
$515.00
+27.6%
06/12/2026
Imron Zafar
Deutsche Bank
Sell
Maintained
$366.00
-9.3%
06/02/2026
Adam Maeder
Piper Sandler
Buy
Reiterated
$580.00
+43.7%
06/02/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
$654.00
+62%
05/28/2026
Joanne Wuensch
Citi
Buy
Reiterated
$590.00
+46.1%
05/28/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
05/05/2026
Matt Miksic
Barclays
Buy
Reiterated
$651.00
+61.2%
04/23/2026
Unknown Analyst
Jefferies
Hold
Reiterated
$515.00
+27.6%
04/22/2026
Mathew Blackman
TD Cowen
Buy
Maintained
$585.00
+44.9%
04/22/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
$550.00
+36.2%
04/22/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$670.00
+65.9%
04/22/2026
Richard Newitter
Truist Financial
Buy
Reiterated
$580.00
+43.7%
04/22/2026
David Rescott
Robert W. Baird
Buy
Maintained
$610.00
+51.1%
04/22/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$650.00
+61%
04/21/2026
Brandon Vazquez
William Blair
Buy
Maintained
$451.00
+11.7%
04/22/2026
Vijay Kumar
Evercore ISI
Hold
Maintained
$480.00
+18.9%
04/20/2026
Anthony Petrone
Mizuho Securities
Hold
Reiterated
$525.00
+30%
04/13/2026
Nico Chen
DBS
Hold
Maintained
$480.00
+18.9%
03/18/2026
Danielle Antalffy
UBS
Hold
Reiterated
$550.00
+36.2%
03/17/2026
Patrick Wood
Morgan Stanley
Buy
Maintained
$650.00
+61%
01/28/2026
Last report
Apr 21, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$2.50 / $2.11
+18.67%beat
Revenue / Est. (USD)
2.77B / 2.62B
+5.84%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
2.44B
2.51B
2.87B
2.77B
Cost of goods sold
822.10M
842.70M
961.90M
940.30M
Cost of revenue
822.10M
842.70M
961.90M
940.30M
Research and development expenses
313.30M
329.40M
352.90M
361.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
561.20M
573.30M
687.10M
613.30M
Operating expense
874.50M
902.70M
1.04B
975.20M
Total operating expenses
1.70B
1.75B
2.00B
1.92B
Operating income
743.40M
759.70M
864.30M
855.30M
Other non operating income
-
-
-
-
EBT including unusual items
832.10M
855.20M
955.60M
940.40M
EBT excluding unusual items
832.10M
855.20M
950.90M
939.80M
Income tax expense
167.90M
146.00M
156.10M
114.40M
Effective tax rate
20.18%
17.07%
16.34%
12.16%
Other operating expenses
-
-
-
-
Net income
658.40M
704.40M
794.80M
821.50M
Net profit margin
26.98%
28.12%
27.73%
29.65%
Earnings per share
2.19
2.40
2.53
2.50
Interest and investment income
113.50M
82.30M
77.50M
85.70M
Interest expense
-
-
-
-
Net interest expenses
113.50M
82.30M
77.50M
85.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
898.70M
919.70M
1.02B
1.06B
Gain or loss from assets sale
-
-
13.70M
-7.90M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer